Boston Scientific (BSX) has announced plans to acquire carotid artery device specialist Silk Road Medical for approximately $1.26 billion. This is a strategic move poised to significantly expand the company’s cardiology portfolio.By paying $27.50 per share, Boston Scientific is offering a 38% premium over Silk Road's volume-weighted average share price over the past 60 days. With this transaction, expected to close in the second half of 2024, Silk Road will become a wholly owned subsidiary of the MedTech gi ...

The Zacks Medical – Products industry’s revenues are expected to continue its growth trajectory on the back of the recovery in demand for surgeries and procedures, new products and expansion into new markets. An earlier-than-expected demand for respiratory products is also boosting sales. The industry players are raising prices of their products and services to cope with the higher costs, thereby benefiting the top and bottom lines. However, the company continues to face challenges due to supply-chain const ...

The most recent trading session ended with Boston Scientific (BSX) standing at $76.31, reflecting a +0.16% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 0.25%. On the other hand, the Dow registered a gain of 0.15%, and the technology-centric Nasdaq increased by 0.03%.Coming into today, shares of the medical device manufacturer had gained 1.1% in the past month. In that same time, the Medical sector gained 0.11%, while the S&P 500 gained 3.34%.The upcoming earni ...

Key TakeawaysBoston Scientific has purchased Silk Road Medical, which makes products to help prevent strokes in patients with carotid artery disease.The company is paying $1.26 billion for Silk Road, or $27.50 per share, a 27% premium to Monday's closing price.Boston Scientific said the acquisition will not be accretive to its adjusted earnings per share until 2026. Shares of Silk Road Medical (SILK) soared in intraday trading Tuesday after Boston Scientific (BSX) announced it was buying the medical device ...

Loading...Loading...Tuesday, Boston Scientific Corporation BSX agreed to acquire Silk Road Medical Inc SILK for $27.50 in cash per share, representing an equity value of approximately $1.26 billion.The per-share price represents an approximate 38% premium to the volume-weighted average share price of Silk Road Medical’s common stock over the past 60 days.Related: Heart Devices Focused Silk Road Medical Stock Gets an Upgrade – Analyst Says New CEO’s Initiatives Sets Stage For ‘Back On Track’Silk Road Medical ...

Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash SUNNYVALE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. ("Silk Road") (NASDAQ:SILK), a leading minimally invasive medical device company for carotid artery procedures, announced today it has entered into a definitive agreement to be acquired by Boston Scientific Corporation ("Boston Scientific") (NYSE:BSX), a global medical technology leader, for $27.50 in cash per share, representing an equity value of approxim ...

Acquisition adds innovative technology for stroke prevention to vascular portfolioMARLBOROUGH, Mass., June 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). ...

In the latest market close, Boston Scientific (BSX) reached $77.41, with a +0.34% movement compared to the previous day. The stock lagged the S&P 500's daily gain of 0.85%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, added 1.53%.Shares of the medical device manufacturer have appreciated by 4.98% over the course of the past month, outperforming the Medical sector's gain of 2.46% and the S&P 500's gain of 3.11%.Market participants will be closely following the financial results of Bosto ...

CHICAGO, June 11, 2024 (GLOBE NEWSWIRE) -- VelocityEHS®, the global leader in enterprise EHS & ESG software solutions, celebrates Boston Scientific for being named the 2024 Verdantix EHS Innovation Excellence EMEA award winner in the category Operational Risk Management. Boston Scientific, a world leader in innovative medical device solutions, received this honor for its manufacturing facility in Cork, Ireland, where it streamlined the permit and contractor management program using the VelocityEHS Control o ...

Boston Scientific (BSX) is well-poised for growth in the coming quarters, backed by its successful expansion of operations across different geographies outside the United States. Its recent acquisitions are expected to drive revenue growth in the long term. Strong solvency is also highly encouraging. Meanwhile, headwinds such as adverse macroeconomic impacts and currency movements raise concerns for Boston Scientific.In the past year, this Zacks Rank #2 (Buy) stock has rallied 48.1% compared with the 3.8% r ...